Are nucleos(t)ide analogues effective against severe outcomes in COVID-19 and hepatitis B virus coinfection?
Hepatology Forum, cilt.2, sa.3, ss.91-96, 2021 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 2 Sayı: 3
- Basım Tarihi: 2021
- Doi Numarası: 10.14744/hf.2021.2021.0027
- Dergi Adı: Hepatology Forum
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.91-96
- Anahtar Kelimeler: Chronic HBV infection, chronic hepatitis, cirrhosis, COVID-19, hepatitis B, nucleos(t)ide analogue treatment
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background and Aim: The impact of chronic hepatitis B virus (HBV) infection and nucleos(t)ide analogue (NUC) treatment on disease severity and clinical outcomes in patients with coronavirus 2019 (COVID-19) is unknown. The objective of this study was to determine whether HBV infection and the use of NUCs impacts mortality in patients with COVID-19. Materials and Methods: A total of 231 adult patients (77 with COVID-19 and HBV coinfection) with a laboratory-confirmed diagnosis of COVID-19 were enrolled in this retrospective study. Univariate and binary logistic regression analysis were performed to evaluate the risk factors for mortality from COVID-19. Results: Patients with COVID-19 and HBV coinfection had a similar rate of mortality to those without HBV coinfection (7.8% vs 9.7%; p=0.627). Cardiovascular disease (odds ratio [OR]: 8.22, 95% confidence interval [CI]: 1.52-44.2; p=0.014) and a high basal aspartate transaminase level (OR: 7.94, 95% CI: 1.81-34.8; p=0.006) were independent predictors of mortality due to COVID-19. In the COVID-19 and HBV coinfection group, the patients who died had a significantly higher median level of HBV DNA than patients who survived (378 IU/mL vs 0 IU/mL; p=0.048). Thirty (39%) patients with HBV coinfection received NUC treatment, and none of these patients died. Conclusion: HBV infection was not associated with mortality in patients with COVID-19, and it seems that NUC treatment for HBV infection might have an antiviral effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.